Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

PHASE1UnknownINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

January 31, 2019

Study Completion Date

April 30, 2019

Conditions
Pancreatic CancerMelanomaSquamous Cell Carcinoma of the Head and NeckProstate Cancer
Interventions
DRUG

Evofosfamide

Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.

DRUG

Ipilimumab

Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

lead

Threshold Pharmaceuticals

INDUSTRY